Health Care [ 5/12 ] | Biotechnology [ 22/75 ]
NYSE MKT | Common Stock
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.
The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients.
It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis.
BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 31, 25 | -21.39 Increased by +2.11% | -5.06 Decreased by -322.73% |
| Nov 12, 25 | -0.29 Increased by +56.53% | -6.08 Increased by +95.23% |
| Aug 13, 25 | -0.19 Decreased by -396.88% | -0.26 Increased by +26.92% |
| May 19, 25 | 0.33 Increased by +376.38% | -0.30 Increased by +210.00% |
| Mar 25, 25 | -21.85 Decreased by -2.63 K% | -20.80 Decreased by -5.02% |
| Nov 12, 24 | -0.67 Decreased by -413.15% | -0.40 Decreased by -66.77% |
| Aug 15, 24 | 0.06 Decreased by -46.67% | -0.87 Increased by +107.38% |
| May 21, 24 | -0.12 Increased by +40.30% | -1.15 Increased by +89.62% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | N/A Decreased by -100.00% | -13.34 M Increased by +8.10% | - - |
| Sep 30, 25 | 0.00 Increased by +100.00% | -9.17 M Decreased by -280.90% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Increased by +100.00% | -6.04 M Decreased by -235.03% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Increased by +100.00% | -7.66 M Increased by +55.80% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 172.00 K Increased by +N/A% | -14.51 M Decreased by -164.31% | Decreased by -8.44 K% Decreased by N/A% |
| Sep 30, 24 | -84.00 K Increased by +5.62% | 5.07 M Increased by +164.09% | Decreased by -6.03 K% Decreased by -167.91% |
| Jun 30, 24 | -2.02 M Decreased by -2.14 K% | 4.47 M Increased by +169.74% | Decreased by -221.67% Decreased by -103.11% |
| Mar 31, 24 | -88.00 K Increased by +3.30% | -17.33 M Decreased by -172.39% | Increased by +19.69 K% Increased by +181.68% |